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116Primary Percutaneous Coronary Intervention in Patients With
Acute Myocardial Infarction, Resuscitated Cardiac Arrest, and
Cardiogenic Shock
The Role of Primary Multivessel Revascularization
Objectives This study sought to assess the impact of multivessel (MV) primary percutaneous coro-
nary intervention (PCI) on clinical outcomes in patients with ST-segment elevation myocardial infarc-
tion (STEMI) presenting with cardiogenic shock (CS) and resuscitated cardiac arrest (CA).
Background The safety and efﬁcacy of MV primary PCI in patients with STEMI and refractory CS is
unknown.
Methods We conducted a multicenter prospective observational study of consecutive STEMI pa-
tients presenting to 5 French centers. Patients were classiﬁed as having single-vessel (SVD) or multi-
vessel (MVD) coronary disease, and underwent culprit-only or MV primary PCI. Baseline characteris-
tics and 6-month survival were compared.
Results Among 11,530 STEMI patients, 266 had resuscitated CA and CS. Patients with SVD (36.5%)
ad increased 6-month survival compared to those with MVD (29.6% vs. 42.3%, p  0.032). Baseline
characteristics were similar in those with MVD undergoing culprit-only (60.9%) or MV (39.1%) pri-
mary PCI. However, 6-month survival was signiﬁcantly greater in patients who underwent MV PCI
(43.9% vs. 20.4%, p  0.0017). This survival advantage was mediated by a reduction in the compos-
ite of recurrent CA and death due to shock (p  0.024) in MV PCI patients. In those with MVD, cul-
prit artery PCI success (hazard ratio [HR]: 0.63; 95% conﬁdence interval [CI]: 0.41 to 0.96, p  0.030)
and MV primary PCI (HR: 0.57; 95% CI: 0.38 to 0.84, p  0.005) were associated with increased
6-month survival.
Conclusions The results of this study suggest that in STEMI patients with MVD presenting with CS
and CA, MV primary PCI may improve clinical outcome. Randomized trials are required to verify
these results. (J Am Coll Cardiol Intv 2013;6:115–25) © 2013 by the American College of Cardiology
FoundationIncreased availability of primary percutaneous coronary
intervention (PCI) has reduced the incidence of cardiogenic
shock (CS) in patients with ST-segment elevation myocar-
dial infarction (STEMI) (1). In STEMI patients with
established CS, prompt primary PCI of the infarct-related
artery (IRA) improves survival (2); however, mortality
remains unacceptably high (50%), and is even worse in
patients who have been resuscitated from cardiac arrest (3).
See page 126
The majority of patients with STEMI and CS have
multivessel coronary artery disease (MVD). Multivessel
disease is more likely to induce widespread myocardial
ischemia and progressive left ventricular dysfunction, and
has been associated with increased mortality (4). Not
surprisingly, multivessel (MV) revascularization during pri-mary PCI has been proposed as a strategy with the potential
to improve outcomes in patients with MVD and persistent
CS. Current societal guidelines concur (5,6); however, there
is little evidence to support this strategy (7), which could
conversely worsen outcomes by increasing the risk of non-
IRA distal embolization, stent thrombosis, and contrast
nephropathy (8).
To investigate the safety and efficacy of MV primary PCI,
we conducted a multicenter study of patients with STEMI,
CS, and resuscitated cardiac arrest, and compared clinical
outcomes in patients treated with either culprit-only or MV
primary PCI.
Methods
Patient population. Between 1998 and 2010, we prospec-
tively collected data from consecutive unselected patients
presenting with STEMI in 5 French centers. The study
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117population was derived from 11,530 patients admitted with
STEMI, among whom 4.3% (n  496) had resuscitated
cardiac arrest, 9.8% (n  1,130) had CS, and 2.4% (n  272)
presented with both resuscitated cardiac arrest and CS (Fig. 1).
Patients were selected for the current study if they had
been resuscitated from cardiac arrest, met the criteria for
STEMI and CS, and had a culprit lesion on coronary
angiography, 24 h after the onset of ischemia. This
patient population was specifically chosen as it represents
the highest-risk patient group encountered by interventional
cardiologists, and in light of the cardiac arrest, are the most
likely to have ongoing global myocardial ischemia. Patients
were excluded if further resuscitation was deemed futile on
arrival at the catheterization laboratory, an alternative cause
of shock was suspected, or if a mechanical complication of
myocardial infarction (MI) was determined before PCI.
The study complied with the Declaration of Helsinki.
Pre-hospital management. Pre-hospital medical care was
performed by the emergency medical service (EMS) (Ser-
vice d’Aide Médicale Urgence) as described previously (3).
External defibrillation; administration of inotropic, para-
lytic, and antiarrhythmic drugs; and mechanical ventilation
were routinely performed according to approved guidelines.
According to the Utstein template (9), resuscitated patients
with obvious extracardiac causes were investigated and
treated according to standard critical care procedures. In the
absence of an obvious extracardiac cause, survivors were
transferred directly to cardiac catheterization laboratories
under continuous electrocardiogram (ECG) monitoring. At
least 1 pre-hospital 12-lead ECG was recorded in all
patients.
In-hospital evaluation and treatment. All patients under-
went a rapid clinical evaluation and immediate coronary
angiography with a view to performing primary PCI.
Hemodynamic status was cautiously evaluated on admission
and during angiography. Our default strategy was to per-
form primary PCI in these high-risk, hemodynamically
unstable patients unless, a mechanical complication, deemed
coronary artery bypass graft (CABG) surgery to be more
appropriate. All decisions regarding the PCI, including the
number of vessels treated, were solely at the discretion of the
treating physician. All patients were treated with intrave-
nous heparin (1 mg/kg body weight) and aspirin (250 to 500
mg) before PCI. Further doses of heparin were given as
required to maintain an activated clotting time of 300 to
350 s. A loading dose of 300 to 600 mg of clopidogrel was
given before PCI, or immediately after the procedure
through a nasogastric tube in unconscious patients.
Intensive medical care was provided in dedicated cardiac
intensive care units for all patients following PCI. Mild
therapeutic hypothermia, renal replacement therapy, and
left ventricular assist devices were used where appropriate.
Data collection and follow-up. Data were prospectively col-
ected using the Utstein-style guidelines for cardiac arrest n9). Adverse cardiac events, including recurrent cardiac
rrest, reinfarction, and early urgent revascularization were
ecorded. Cerebral Performance Categories Scale scores of
utcome, graded 1 to 4, were calculated at hospital dis-
harge for all survivors as follows: 1  conscious and alert
ith good cerebral performance; 2  conscious with mod-
rate cerebral disability; 3  conscious with severe disability
nd dependent on others for activities of daily living; and
 comatose or persistent vegetative state (10). Clinical
ollow-up was performed by hospital visit or patient/next-
f-kin telephone interview at 6 months.
Study deﬁnitions. Cardiogenic
hock was defined on admission
ccording to the clinical criteria
escribed in the SHOCK (Should
e Emergently Revascularize
ccluded Coronaries for Cardi-
genic Shock) trial (2): systolic
lood pressure 90 mm Hg for
30 min or the requirement for
upportive measures to maintain
lood pressure 90 mm Hg, and
vidence of end-organ hypoper-
usion (cool extremities, urine
utput 30 ml/h, and a heart
ate 60 beats/min). The diag-
osis of CS was verified by the
ssessment of the original EMS
atient encounter forms by an
ndependent physician.
Acute MI was defined as
CG evidence of 2-mm ST-
egment elevation in 2 contig-
ous leads or a left bundle branch
lock or a posterior infarction
ith anterior ST-segment de-
ression, and at least 1 culprit
esion on angiography. Cardiac
rrest was defined as the cessa-
ion of cardiac mechanical activ-
ty as confirmed by the absence
f signs of circulation (9). A
ardiac arrest in medical care
ndicated an arrest occurring either in-hospital or in the
resence of the EMS.
Multivessel coronary disease was defined as the presence
f an additional significant stenosis (70%) in a major
2.5-mm diameter) non-IRA, or as a distal left main
esion with significant stenosis of the ostia of both the
aughter arteries. Immediate PCI of a stenosis 70% in a
on-IRA during the index procedure, not including
ranches of the IRA, and PCI of both branches of the distal
eft main defined MV primary PCI. Intervention to a
Abbreviations
and Acronyms
CA  cardiac arrest
CABG  coronary artery
bypass grafting
CI  confidence interval
CK  creatinine kinase
CS  cardiogenic shock
ECG  electrocardiogram
EMS  emergency medical
service
HR  hazard ratio
IRA  infarct-related artery
MI  myocardial infarction
MV  multivessel
MVD  multivessel coronary
disease
PCI  percutaneous
coronary intervention
ROSC  resumption of
spontaneous circulation
STEMI  ST-segment
elevation myocardial
infarction
SVD  single-vessel
coronary disease
TIMI  Thrombolysis In
Myocardial Infarction
ULN  upper limit of normalon-IRA remote from the index procedure was not consid-
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118ered as MV primary PCI. Angiographic success in the IRA
was defined as residual stenosis 30% and a final Throm-
bolysis in Myocardial Infarction (TIMI) flow grade 2.
Reinfarction was defined as follows: 1) if the peak
creatinine kinase (CK)-MB fraction (or CK) from the index
infarction had not yet been reached: recurrent ischemic
symptoms 20 min in duration or new ECG changes
consistent with MI, and the peak CK-MB (or CK in the
absence of CK-MB) level measured within 24 h after the
event was elevated by at least 50% above the previous level;
2) if the elevated CK-MB (or CK) level from the index
infarction was falling or had returned to normal: recurrent
ischemic symptoms lasting 20 min in duration, or new
ECG changes consistent with MI, and a new elevation of
CK-MB (or CK) greater than the upper limit of normal
(ULN) if the patient was being treated medically, or
CK-MB/CK 3 ULN within 24 h post-PCI if the
K-MB (or CK) level has returned to ULN, or a rise by
50% above the previous nadir level (and 3 ULN if
ost-PCI) if the CK-MB (or CK) level has not returned to
ULN (11). The cause of death was defined as follows: CS,
eath due to persistent hypotension, refractory heart failure,
r multiorgan failure; anoxia death due to a persistent
egetative state; arrhythmia death due to recurrent intrac-
able cardiac arrest; sepsis death, death due to overwhelming
ystemic infection. All clinical events, including the cause of
eath, were adjudicated by 2 independent physicians
linded to the patient’s initial treatment strategy.
Outcome variables. The primary outcome measure of the
study was 6-month survival. Secondary endpoints included
death due to CS, recurrent cardiac arrest, and a composite of
ST-Segment Elevati
n=
Cardiogenic Shock 
n=1130 (9.8%) 
Shock & 
n=27
Mechanical Complicaon 
n=6 (2.2%) 
Single Vessel Disease 
n=97 (36.5%) 
Six-Month Survival  
42.3% 
Six
C
Figure 1. Study Population
Schematic representation of the study population. PCI  percutaneous coronathese endpoints.Statistical analysis. Continuous variables are presented as
mean  SD or median and (interquartile range), and were
compared with the Student t test or Mann-Whitney test,
according to distribution. Categorical variables are pre-
sented as numbers and percentages, and were compared
using the chi-square test or Fisher exact test. Survival at 6
months was calculated and analyzed by the Kaplan-Meier
method, and differences between Kaplan-Meier curves were
analyzed with the log-rank test. A multiple Cox regression
analysis was performed to assess predictors of 6-month
survival, including all baseline and treatment characteristics
associated with 6-month survival in the univariate analysis
(p  0.10), and had availability in the database 85%. The
ffect of MV primary PCI on 6-month survival in patients
ith MVD was assessed by a separate multiple Cox regres-
ion analysis. A 2-tailed p value of 0.05 was considered
tatistically significant. All statistical analyses were per-
ormed using SPSS version 17.0 (SPSS, Chicago, Illinois).
esults
Baseline demographic and clinical characteristics. A total of
272 STEMI patients met the criteria for resuscitated cardiac
arrest and CS. Six patients with mechanical complications
were referred for urgent CABG and were excluded from the
analysis. The baseline demographics of the remaining 266
patients are presented in Table 1. Cardiac arrests occurred
most commonly at home (35.4%), and the median no-flow,
arrest to defibrillation, and resumption of spontaneous
circulation (ROSC) intervals were (median [interquartile
range]) 5.0 [2.0 to 14.0], 15.0 [6.0 to 24.5], and 25.0 [11.5
yocardial Infarction 
0 
c Arrest 
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n=496 (4.3%) 
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119underlying arrhythmia in 60.2% of cases, and the initial
ECG demonstrated ST-segment elevation in 86.5%. Pre-
hospital thrombolysis was performed in 14.6% of patients.
Mean admission systolic and diastolic blood pressures were
86.5  18.0 mm Hg and 55.9  13.8 mm Hg, respectively,
despite inotropic support in 94.4% (Table 2).
Angiographic and treatment data. The culprit lesion was
ost commonly located in the left anterior descending
oronary (51.9%), and was in the left main in 9.8% of cases
Table 3). The majority of patients had MVD (63.5%), and
8.8% had a non-IRA chronic total occlusion. Despite the
igh prevalence of MVD, most patients underwent culprit-
nly PCI (75.2%) (Table 4). Culprit-artery stenting was
erformed in 95.1%, glycoprotein IIb/IIIa inhibitors were
sed in 12.4%, and thromboaspiration in 41%. Angio-
raphic success in the IRA was achieved in 80.5% of cases.
he majority of patients required mechanical ventilation
77.4%) and intra-aortic balloon counterpulsation
Table 1. Baseline Characteristics of the Study Population
All Patients
(N  266)
SVD
(n  97)
M
(n 
Age, yrs 63.1 13.0 56.1 13.6 67.2
Male 195 (73.3) 71 (73.2) 124
Body mass index, kg/m2 25.3 [23.0–28.4] 25.8 [21.9–28.6] 25.1 [2
Cardiac risk factors, %
Hypertension 115 (43.2) 30 (30.9) 85
Hyperlipidemia 105 (39.5) 33 (34.0) 72
Current/past smoker 88 (33.1) 33 (34.0) 55
Diabetes mellitus 61 (22.9) 18 (18.6) 43
Family history of CAD 24 (9.0) 6 (6.2) 18
Prior MI 59 (22.2) 14 (14.4) 45
Prior PCI 49 (18.4) 15 (15.5) 34
Prior CABG 10 (3.8) 1 (1.0) 9
Location of cardiac arrest
Home 94 (35.4) 36 (37.1) 58
Public place 86 (32.3) 34 (35.1) 53
In medical care 86 (32.3) 27 (27.8) 58
Cardiac arrest intervals, min*
No-ﬂow 5.0 [2.0–14.0] 5.0 [2.0–10.0] 6 [2
Arrest to deﬁbrillation 15.0 [6.0–24.5] 15.0 [8.0–25.0] 15.0 [5
Arrest to ROSC 25.0 [11.5–35.0] 28.0 [15.0–45.0] 25.0 [1
First monitored rhythm
Ventricular tachycardia 26 (9.8) 6 (6.2) 20
Ventricular ﬁbrillation 160 (60.2) 63 (65.0) 97
Asystole 61 (22.9) 19 (19.5) 42
Unknown/other 19 (7.1) 9 (9.3) 10
Deﬁbrillation 222 (83.5) 86 (88.7) 136
Values are mean SD, n (%), or median [interquartile range]. *Based on 169 patients.
CABG coronary artery bypass grafting; CAD coronary artery disease; MImyocardial infarcti
resumption of spontaneous circulation; SVD single vessel disease.76.3%). Mild therapeutic hypothermia was performed in2.2%, and left ventricular assist devices were used in 8
3%) patients.
Clinical outcomes. Death in the catheterization laboratory
or within 24 h of hospital admission occurred in 7.9% and
29.3%, respectively (Table 5). A small proportion of patients
had reinfarction (1.9%) or repeat emergent PCI (3.8%).
Recurrent in-hospital cardiac arrest after primary PCI
occurred in almost one-third of patients (32.7%). Six-
month clinical follow-up was available in all patients.
Overall 6-month survival was 34.6%. Refractory CS was the
most common cause of death (60.2%). The median duration
to death was 2.0 [1.0 to 9.0] days. Among survivors, the
majority recovered good/moderate cerebral performance
(89.5%), and 30.4% underwent further nonurgent
revascularization.
Single-vessel and multivessel disease. Compared to those
with SVD (36.5%), patients with MVD (63.5%) were more
likely to have a history of hypertension (30.9% vs. 50.3%,
p Value
MVD
p Value
Culprit-Only Primary PCI
(n  103)
MV Primary PCI
(n  66)
p0.001 68.5 11.8 65.0 12.4 0.088
0.999 74 (71.8) 50 (66.0) 0.598
.4] 0.796 26.0 [23.0–33.1] 25 [23.3–27.0] 0.288
0.003 50 (48.5) 35 (53.0) 0.637
0.193 42 (40.8) 30 (45.5) 0.633
0.892 32 (31.1) 23 (34.8) 0.618
0.227 26 (25.2) 17 (25.8) 0.999
0.27 10 (9.7) 8 (12.1) 0.619
0.022 31 (30.1) 14 (21.2) 0.217
0.412 23 (22.3) 11 (16.7) 0.434
0.099 5 (4.9) 4 (6.1) 0.738
0.69 35 (34.0) 23 (34.8) 0.999
0.588 34 (33.0) 19 (27.8) 0.613
0.339 34 (34.0) 24 (36.4) 0.74
] 0.412 10.0 [3.0–15.0] 5 [2.0–12.0] 0.186
] 0.313 15.0 [6.0–25.0] 12 [5.0–20.0] 0.412
.0] 0.136 25.0 [15.0–30.0] 18.0 [10.0–31.3] 0.262
0.197 13 (12.6) 7 (10.6) 0.809
0.244 57 (55.3) 40 (60.6) 0.527
0.365 28 (27.2) 14 (21.2) 0.467
0.329 5 (4.9) 5 (7.6) 0.515
0.089 86 (83.5) 50 (75.8) 0.237
multivessel; MVDmultivessel disease; PCI percutaneous coronary revascularization; ROSCVD
169)
 12.1
(73.4)
3.2–28
(50.3)
(42.6)
(32.5)
(25.4)
(10.7)
(26.6)
(20.1)
(5.3)
(34.3)
(31.4)
(34.3)
.3–15.0
.3–23.0
0.0–30
(11.8)
(57.4)
(24.9)
(5.9)
(80.5)
on; MVp 0.003), prior MI (14.4% vs. 26.6%, p 0.022), and present
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120with a lower systolic blood pressure (94.8  27.2 mm Hg vs.
82.6  19.2 mm Hg, p  0.001). An average 2.5  0.5
essels were significantly diseased (70%) in the MVD
ohort. Six-month survival was significantly lower in
atients with MVD (42.3% vs. 29.6%, p  0.032) (Table 5,
Fig. 2A).
Culprit-only or MV primary PCI in MVD. Of the 169 patients
with MVD, 103 (60.9%) had culprit-only primary PCI, and
66 (39.1%) had MV primary PCI. There was a higher
incidence of initial TIMI flow grade 0 (75.7% vs. 56.1%,
p  0.011) and a right coronary artery IRA (30.1% vs.
5.2%, p  0.029) in the culprit-only primary PCI group.
istal left main lesions requiring intervention to both
aughter branches were classified as MV PCI, and there-
ore, left main IRAs were more common in the MV primary
CI group (7.8% vs. 21.2%, p  0.018). Intra-aortic
ounterpulsation was performed in 75.7% of culprit-only
rimary PCI patients and in 83.3% of MV primary PCI
ases (p  0.256). In the culprit-only primary PCI group,
here were 2 cases where PCI of a non-IRA vessel was
ttempted and failed. In the MV primary PCI group, the
ean number of non-IRA vessels attempted was 1.3  0.5,
ith 1.2  0.4 vessels successfully treated, and complete
oronary revascularization achieved in 63.6%. Predictably,
ess contrast media was used in the culprit-only primary PCI
Table 2. Patient Characteristics on Hospital Admission
All Patients
(N  266)
SVD
(n  97)
Pre-arrest chest pain 172 (64.7) 66 (68.0)
Pre-infarct angina 84 (31.6) 31 (32.0)
Pre-hospital thrombolysis 39 (14.6) 18 (18.6)
Electrocardiographic ﬁndings
ST-segment elevation 230 (86.5) 88 (90.7)
ST-segment depression 12 (4.5) 4 (4.1)
LBBB 24 (9.0) 5 (5.2)
Third-degree heart block 26 (9.8) 9 (9.3)
Ejection fraction, %* 31.0 9.3 31.4 9.4
Hemodynamic parameters
Systolic blood pressure, mm Hg 86.5 18.0 94.8 27.2
Diastolic blood pressure, mm Hg 55.9 13.8 58.3 16.3
Heart rate, beats/min 92.2 24.0 97.9 30.1
Laboratory ﬁndings on admission
pH† 7.2 0.2 7.2 0.2
Lactate‡ 8.2 3.7 7.8 3.5
Glucose† 8.3 3.2 8.1 2.9
Estimated GFR, ml/min 75.1 29.4 76.1 33.0
Peak creatinine kinase (4 h), IU/L§ 3,600 [2,220–6,000] 3,338 [2,075–5,147]
Values are mean  SD, n (%), or median [interquartile range]. Based on *139, †142, ‡139, and §18
LBBB left bundle branch block; GFR glomerular infiltration rate; other abbreviations as in Taroup (170.3  67.4 ml vs. 221.7  83.1 ml, p  0.0001).Six-month survival was significantly greater in those
ndergoing MV primary PCI compared with those who had
ulprit-only intervention (43.9% vs. 20.4%, p  0.0017)
Table 5, Fig. 2B). This survival advantage was mediated by
significant reduction in the composite endpoint of recur-
ent cardiac arrest/shock death in the MV primary PCI
roup (50.0% vs. 68.0%, p  0.024).
Association of baseline characteristics and treatment with
6-month mortality. Univariable analysis of the entire popu-
lation revealed that 4 characteristics were associated with
6-month mortality (p  0.10): 1) an asystolic cardiac arrest;
2) a right coronary IRA; 3) MV primary PCI; and 4)
angiographic success in the IRA (Table 6). Following
adjustment, an asystolic cardiac arrest (hazard ratio [HR]:
1.58; 95% confidence interval [CI]: 1.07 to 2.35, p 0.022)
remained a predictor of 6-month mortality and a right
coronary IRA (HR: 0.65; 95% CI: 0.49 to 1.02, p 0.025),
and PCI success (HR: 0.49; 95% CI: 0.34 to 0.72, p 
0.0001) were associated with 6-month survival by multivari-
able analysis.
In patients with MVD, a right coronary IRA (HR: 0.54;
95% CI: 0.34 to 0.85, p  0.009), MV primary PCI (HR:
0.57; 95% CI: 0.36 to 0.80, p  0.002) and angiographic
success in the IRA (HR: 0.65; 95% CI: 0.43 to 1.00, p 
0.050) were associated with 6-month survival following
MVD
 169) p Value
MVD
p Value
Culprit-Only Primary PCI
(n  103)
MV Primary PCI
(n  66)
07 (63.3) 0.505 67 (65.0) 40 (60.6) 0.625
53 (31.4) 0.999 36 (35.0) 17 (25.8) 0.237
21 (12.5) 0.208 15 (14.6) 6 (9.2) 0.251
42 (84.1) 0.14 88 (85.4) 54 (81.8) 0.528
8 (4.7) 0.999 3 (2.9) 5 (7.6) 0.265
19 (11.2) 0.12 12 (11.7) 7 (10.6) 0.999
17 (10.1) 0.999 11 (10.7) 6 (9.1) 0.799
.6 9.2 0.594 30.3 9.0 31.0 9.6 0.493
.6 19.2 0.001 83.0 21.2 82.0 15.7 0.742
.8 14.8 0.17 55.0 16.1 54.4 12.7 0.798
.8 20.8 0.103 98.0 21.2 95.0 20.0 0.36
.2 0.2 0.973 7.2 0.2 7.2 0.2 0.999
.3 4.0 0.439 8.3 4.3 8.1 3.9 0.82
.4 3.4 0.466 8.2 3.1 8.2 3.6 0.999
.7 24.1 0.497 75.4 37.5 72.9 22.8 0.627
[2,221–6,509] 0.423 4,139 [2,427–6,500] 3,500 [2,055–7,485] 0.655
nts.(n
1
1
30
82
54
96
7
8
8
73
3,708
5 patieadjustment for other variables.
s as in T
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121Discussion
In the present study, we found that STEMI patients with
CS, resuscitated cardiac arrest, and MVD, had significantly
greater survival following MV primary PCI compared with
culprit-only primary PCI. The results of this study suggest
that more complete upfront revascularization has the po-
tential to improve outcomes in these critically ill patients.
The SHOCK trial confirmed that prompt revasculariza-
tion improves survival in CS (2); however, the optimal
revascularization strategy for shock patients with MVD is
not clear. This is of particular relevance because MVD
occurs in up to 87% of patients with CS (12) and is
associated with increased mortality (4,13). Certainly, there
is a rationale for more complete revascularization in MVD
patients with CS refractory to IRA intervention. Mortality
in CS is directly related to the degree of myocardial
ischemia and the extent of acute left ventricular dysfunc-
tion (2). Therefore, treatment of significant non-IRA
stenoses which supply a large area of myocardium has the
potential to improve left ventricular function, by enhanc-
ing perfusion of the periinfarct area and minimizing
non-IRA ischemia. Pathological studies have also dem-
Table 3. Angiographic Characteristics
All Patients
(N  266)
SVD
(n  97)
MVD
(n  1
Culprit lesion
Left main 26 (9.8) 4 (4.1) 22 (1
Left anterior descending 138 (51.9) 62 (63.9) 76 (4
Circumﬂex 36 (13.5) 9 (9.3) 27 (1
Right coronary 63 (23.7) 22 (22.7) 41 (2
Bypass graft 3 (1.1) 0 (0.0) 3 (1
Number of diseased vessels 1.9 0.8 1.0 0.0 2.5
1 97 (36.5) 97 (100)
2 86 (32.3) 86 (5
3 83 (31.2) 83 (4
Bifurcation lesion 67 (25.2) 25 (25.8) 42 (2
Stenosis severity, % 94.4 14.2 94.6 17.7 94.4
Pre-PCI TIMI ﬂow grade
0 188 (70.7) 73 (75.3) 115 (6
1 14 (5.2) 4 (4.1) 10 (5
2 22 (8.3) 3 (3.1) 19 (1
3 42 (15.8) 17 (17.5) 25 (1
Visible thrombus 232 (87.2) 87 (89.7) 145 (8
Stent thrombosis 18 (6.8) 5 (5.2) 13 (7
Drug-eluting stent 11 (61.1) 2 (40.0) 9 (6
Bare-metal stent 7 (38.9) 3 (60.0) 4 (3
Nonculprit CTO 50 (18.8) 50 (2
Values are mean SD or n (%).
CTO chronic total occlusion; TIMI Thrombolysis In Myocardial Infarction; other abbreviationonstrated that those who die from MI frequently haveevidence of multiple separate thrombi in separate terri-
tories, despite a clear culprit lesion (14).
In the setting of nonshock STEMI, MV primary PCI is
inappropriate (5,6), as several trials have illustrated the
deleterious effects of this approach (15–18). By contrast, the
safety and efficacy of MV primary PCI in STEMI with CS
is unclear. Current societal guidelines support MV primary
PCI as a possible treatment strategy for refractory CS (5,6),
though supporting evidence is insufficient. Analysis of the
PCI cohort in the SHOCK trial (n  82) suggested that
MV primary PCI was associated with increased 1-year
mortality (19). However, PCI in the SHOCK trial does not
reflect contemporary practice: 34% received a stent; and only
71% had angiographic success (final TIMI flow grade 2).
In the current study, the IRA was stented in 95.1%, and
angiographic success was achieved in 80.5%.
Previous retrospective analyses of large PCI databases
have investigated the effect of multivessel PCI on clinical
outcomes in patients with STEMI and CS, with somewhat
conflicting results (20,21). Cavander et al. (20) found that
multivessel PCI was associated with increased mortality at 1
year, whereas an analysis by Bauer et al. (21) did not find
p Value
MVD
p Value
Culprit-Only Primary PCI
(n  103)
MV Primary PCI
(n  66)
0.019 8 (7.8) 14 (21.2) 0.018
0.003 45 (43.7) 31 (47.0) 0.752
0.14 16 (15.5) 11 (16.7) 0.833
0.881 31 (30.1) 10 (15.2) 0.029
0.556 3 (2.9) 0 (0.0) 0.282
2.5 0.5 2.5 0.5 0.999
54 (52.4) 32 (48.5) 0.639
49 (47.6) 34 (51.5) 0.639
0.884 20 (19.4) 22 (33.3) 0.046
0.923 95.0 16.6 93.4 17.5 0.55
0.263 78 (75.7) 37 (56.1) 0.011
0.776 5 (4.9) 5 (7.6) 0.515
0.021 10 (9.7) 9 (13.6) 0.461
0.602 10 (9.7) 15 (22.7) 0.026
0.447 92 (89.3) 53 (80.3) 0.117
0.613 8 (7.7) 5 (7.6) 0.999
0.338 6 (75.0) 3 (60.0) 0.999
0.708 2 (25.0) 2 (40.0) 0.644
33 (32.0) 17 (25.8) 0.49
able 1.69)
3.0)
5.0)
6.0)
4.2)
.8)
0.5
0.9)
9.1)
4.9)
16.9
8.0)
.9)
1.2)
4.9)
5.8)
.7)
9.2)
0.8)
9.6)multivessel PCI to have any impact on in-hospital mortality.
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122By contrast, the current study observed a considerable
survival advantage associated with MV primary PCI. These
disparate results must be viewed within the context of the
patient population enrolled and the limitations of observa-
tional study design. The current study included the highest-
risk cohort of patients studied to date, with both STEMI
and resuscitated cardiac arrest, in an attempt to ensure the
presence of shock and global myocardial ischemia. Previous
studies have included lower-risk patient populations: intra-
aortic balloon pump use (11.1% to 33.3%) and in-hospital
mortality (36.5% to 48.8%). The inclusion of nonshock
patients in these analyses may have mitigated any benefit
associated with MV primary PCI. Furthermore, the pro-
spective design of the current study afforded the availability
of individual patient data, thus ensuring adherence to the
patient selection criteria and the exclusion of patients with
late presentations after symptom onset or those who under-
went staged MV PCI.
The survival advantage observed in patients undergoing
MV primary PCI was mediated by a reduction in events
directly related to CS: recurrent cardiac arrest and death due
to shock (68% vs. 50%, p  0.024). A reduction in the
verall myocardial ischemic burden in these critically ill
atients is a possible explanation for these results. The
quivalent 6-month survival in patients with MVD under-
oing MV primary PCI (43.9%) and those with SVD
42.3%) are consistent with this hypothesis. Moreover, these
ata suggest that although complete revascularization results
n a survival benefit in these unstable patients, there is a
imit to what can be achieved with revascularization. How-
Table 4. Percutaneous Coronary Intervention
All Patients
(N  266)
SVD
(n  97)
Thromboaspiration 109 (41.0) 42 (43.3)
GP IIb/IIIa receptor antagonists 33 (12.4) 15 (15.5)
Stent placement 253 (95.1) 90 (92.8)
Total stent length, mm 28.2 17.8 24.1 12
Total number of stents 1.7 1.1 1.2 0.7
Contrast volume, ml 178.8 74.6 158.8 64
Angiographic success in IRA 214 (18.5) 83 (85.6)
Post-PCI TIMI ﬂow grade 3 47 (17.7) 12 (12.4)
Residual stenosis 30% 18 (6.8) 6 (6.2)
IRA no-reﬂow 29 (10.9) 8 (8.2)
IRA thrombus embolization 14 (5.3) 3 (3.1)
IRA side branch occlusion 3 (1.1) 1 (1.1)
Total number of vessels treated 1.3 0.6
Number of non-IRA vessels successfully treated 0.3 0.6
Values are mean SD or n (%).
GP glycoprotein; IRA infarct-related artery; other abbreviations as in Tables 1 and 3.ver, among survivors, favorable neurological outcomes wereobserved (89.5%), and thus, an initial aggressive treatment
strategy is probably warranted.
Previous publications have identified early revasculariza-
tion, left ventricular function, coronary stenting, patient age,
and successful revascularization (TIMI flow grade2) to be
of critical importance when treating patients with CS
(2,22,23). Angiographic success in the IRA was also an
independent predictor of survival (HR: 0.54 95% CI: 0.37
to 0.78, p 0.001) in the current study, as was MV primary
PCI in those with MVD (HR: 0.57; 95% CI: 0.38 to 0.84,
p  0.005).
Urgent CABG is another possible strategy for treating
patients with STEMI and CS (24). However, clinical practice
reflects physician preference for PCI, as a more rapid, less
invasive revascularization strategy: the rate of primary PCI for
CS has increased (27.4% to 54.4%), whereas the rate of CABG
remains stable (2.1% to 3.2%) (1).
Ultimately, the revascularization strategy for each patient
with STEMI and CS should be individualized. In patients
with MVD, the hemodynamic status should be reassessed
following PCI of the IRA. If CS persists, MV primary PCI
should be considered, depending on the complexity of the
nonculprit lesions and their capacity to induce myocardial
ischemia. We provide preliminary evidence that this
strategy may improve clinical outcomes, supporting what
is intuitively proposed by practice guidelines and prac-
ticed by physicians worldwide, and underscoring the need
for adequately powered randomized trials to define the
role of more complete revascularization in these critically
MVD
(n  169) p Value
MVD
p Value
Culprit-Only
Primary PCI
(n  103)
MV Primary
PCI
(n  66)
67 (39.6) 0.605 41 (39.8) 26 (39.4) 0.999
18 (10.7) 0.254 10 (9.7) 8 (12.1) 0.619
163 (96.4) 0.238 96 (93.2) 65 (98.5) 0.151
30.2 18.9 0.004 26.2 18.7 33.0 17.1 0.018
2.0 1.1 0.0001 1.6 0.9 2.6 1.1 0.0001
190.3 77.9 0.0008 170.3 67.4 221.7 83.1 0.0001
131 (77.5) 0.148 78 (75.7) 53 (80.3) 0.573
35 (20.7) 0.097 23 (22.3) 12 (18.1) 0.564
12 (7.1) 0.999 10 (9.7) 2 (3.0) 0.13
21 (12.4) 0.316 17 (16.5) 4 (6.1) 0.056
11 (6.5) 0.269 9 (8.7) 2 (3.0) 0.205
2 (1.2) 0.999 1 (1.0) 1 (1.5) 0.999
1.4 0.6 2.2 0.4
0.45 0.61 1.2 0.4.9
.1ill patients.
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PCI. MV  multivessel; PCI  percutaneous coronary intervention.
CPC Cerebral Performance Categories; other abbreviations as in Table 1.
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123Study limitations. The present study is a nonrandomized,
bservational registry, and is thus limited by patient
election bias. The decision to perform primary culprit-
nly or MV primary PCI was based on operator prefer-
nce. Although the baseline clinical and angiographic
haracteristics were well matched between patients un-
ergoing culprit-only or MV primary PCI, the culprit-
nly group tended to be older; have longer no-flow, arrest
o defibrillation, and ROSC intervals; and were more
ikely to have TIMI 0 flow grade on presentation. These
actors could have resulted in inferior outcomes in the
ulprit-only cohort. Unrecognized confounding variables
lso have the potential to influence nonrandomized
esults. At the time of study conception, it was not
ecognized that intervals, such as the door to balloon and
rst medical contact to balloon were associated with
mproved survival in STEMI. These intervals would have
rovided useful additional information. Similarly, serum
actate levels and the resuscitation intervals were not
ested in the multivariate analysis because the data were
ot available in 85% of cases. However, we have
reviously identified these factors as independent predic-
ors of survival in STEMI patients with resuscitated
ardiac arrest (3). Despite current recommendations, the
se of therapeutic hypothermia worldwide remains poor
22). In the current study, therapeutic hypothermia was
sed in only 22.2% of cases, and more extensive imple-
p Value
MVD
p Value
Culprit-Only Primary PCI
(n  103)
MV Primary PCI
(n  66)
0.999 8 (7.8) 5 (7.6) 0.999
0.999 35 (34.0) 15 (22.7) 0.125
0.999 1 (1.0) 2 (3.0) 0.561
0.099 5 (4.9) 4 (6.1) 0.738
0.786 36 (35.0) 18 (27.3) 0.316
0.032 82 (79.6) 37 (56.1) 0.0017
0.03 54 (67.5) 22 (61.1) 0.532
0.999 9 (11.3) 5 (13.9) 0.76
0.017 16 (20.0) 8 (22.2) 0.807
0.999 1 (1.3) 1 (2.8) 0.999
0.04 70 (68.0) 33 (50.0) 0.024
0.201 2.0 [1.0–8.8] 10.0 [2.0–20.0] 0.201
0.0005 10 (47.6) 9 (31.0) 0.255
0.029 3 (6.5) 3 (10.3) 0.686
0.177 18 (78.3) 27 (90.0) 0.272
0.177 5 (21.7) 3 (10.0) 0.272Figure 2. Primary Endpoint at 6 Months
Survival to 6 months in patients with (A) single-vessel (SVD) or multivessel
(MVD) coronary disease, or (B) MVD undergoing culprit-only or MV primaryTable 5. Clinical Outcomes
All Patients
(N  266)
SVD
(n  97)
MVD
(n  169)
Death in catheterization laboratory 21 (7.9) 8 (7.2) 13 (7.7)
Death within 24 h 78 (29.3) 28 (28.9) 50 (29.6)
Reinfarction 5 (1.9) 2 (2.1) 3 (1.8)
Repeat emergent PCI 10 (3.8) 1 (1.0) 9 (5.3)
Recurrent cardiac arrest 87 (32.7) 33 (34.0) 54 (32.0)
6-month mortality* 174 (65.4) 55 (56.7) 119 (70.4)
Shock death 102 (59.6) 26 (47.3) 76 (65.5)
Arrhythmic death 21 (12.3) 7 (12.7) 14 (12.1)
Anoxic death 45 (26.3) 21 (38.2) 24 (20.7)
Sepsis death 3 (1.8) 1 (1.8) 2 (1.7)
Composite of recurrent cardiac
arrest and shock death
149 (56.0) 46 (47.4) 103 (60.9)
Time to in-hospital death, days 2.0 [1.0–9.0] 2.0 [1.0–7.0] 2.0 [1.0–9.5]
Scheduled nonurgent PCI† 22 (23.9) 3 (7.1) 19 (38.0)
Scheduled nonurgent CABG† 6 (6.5) 0 (0.0) 6 (12.0)
Hospital discharge CPC score†
Favorable (1 or 2) 85 (89.5) 40 (95.2) 45 (84.9)
Not favorable (2 or 3) 10 (10.5) 2 (4.8) 8 (15.1)
Values are mean SD, median [interquartile range], or n (%). *Deceased patients; †survivors only.entation may have improved outcomes (25).
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124Conclusions
The results of this study suggest that in STEMI patients with
MVD presenting with CS and cardiac arrest, MV primary PCI
may improve clinical outcome. Adequately powered prospective
Table 6. Cox Regression Analysis for Predictors of 6-Month Mortality
Simple Cox Regression Multiple Cox Regression
Hazard
Ratio 95% CI
p
Value
Hazard
Ratio 95% CI p Value
All patients, N  266
Age 1.0 0.99–1.02 0.163
Male 0.9 0.65–1.26 0.539
Diabetes 1.3 0.93–1.84 0.13
Asystole 1.55 1.05–2.30 0.028 1.58 1.07–2.35 0.022
Arrest in medical
care
0.76 0.50–1.16 0.203
Systolic blood
pressure
1.01 0.99–1.01 0.186
Pre-hospital
thrombolysis
0.96 0.62–1.48 0.852
Non-target CTO 1.29 0.95–1.91 0.123
Right coronary IRA 0.71 0.49–1.03 0.067 0.65 0.44–0.95 0.025
Left main IRA 0.79 0.47–1.34 0.381
MVD 1.26 0.92–1.73 0.156
Pre-PCI TIMI
grade 0
1.02 0.72–1.41 0.916
Thrombus
aspiration
0.94 0.65–1.34 0.723
MV PCI 0.69 0.48–0.99 0.048 0.70 0.48–1.01 0.06
PCI success 0.6 0.42–0.86 0.006 0.49 0.34–0.72 0.0001
Hypothermia 1.03 0.69–1.53 0.903
MVD only, n  169
Age 1.0 0.99–1.02 0.969
Male 0.9 0.60–1.34 0.595
Diabetes 1.39 0.93–2.07 0.11
Asystole 1.51 0.93–2.45 0.101
Arrest in medical
care
0.9 0.55–1.46 0.662
Systolic blood
pressure
1.01 0.99–1.02 0.337
Pre-hospital
thrombolysis
0.96 0.62–1.48 0.852
Right coronary IRA 0.68 0.43–1.05 0.083 0.54 0.34–0.85 0.009
Left main IRA 0.59 0.33–1.08 0.085 0.55 0.30–1.01 0.054
Non-target CTO 1.29 0.95–1.91 0.123
MVD 1.26 0.92–1.73 0.156
Pre-PCI TIMI ﬂow
grade 0
1.19 0.80–1.77 0.396
Thrombus
aspiration
0.99 0.65–1.50 0.945
MV PCI 0.55 0.37–0.81 0.003 0.53 0.36–0.80 0.002
PCI success 0.59 0.39–0.90 0.014 0.65 0.43–1.00 0.047
Hypothermia 0.79 0.47–1.35 0.391
CI confidence interval; other abbreviations as in Tables 1, 3, and 4.randomized clinical trials are required to verify these results.Reprint requests and correspondence: Dr. Darren Mylotte,
Institut Cardiovasculaire Paris Sud, Institut Hospitalier Jacques
Cartier, 6 Avenue du Noyer Lamber, 91300, Massy, France.
E-mail: darrenmylotte@gmail.com.
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